Elacestrant - Radius Health

Drug Profile

Elacestrant - Radius Health

Alternative Names: RAD 1901

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eisai Co Ltd
  • Developer Radius Health Inc.
  • Class Antineoplastics; Osteoporosis therapies; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Selective estrogen receptor degraders; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer
  • Discontinued Vasomotor symptoms

Most Recent Events

  • 10 May 2018 Radius Health plans a phase III trial for Breast cancer (Metastatic disease, Monotherapy, Second-line therapy or higher, Late-stage disease), in the second half of 2018 (based on EMA and FDA feedback)
  • 28 Feb 2018 No recent reports of development identified for phase-I development in Breast-cancer(Late-stage disease, Metastatic disease) in USA (PO)
  • 07 Dec 2017 Discontinued - Phase-I for Vasomotor symptoms (In volunteers) in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top